Tuesday 19th May 2020: Sydney
GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target, Miltuximab®.
Dr Maria Lund, Pre-Clinical Lead at GlyTherix has written a definitive review on the role of Glypican-1 in the tumour microenvironment. Dr Dmitry Polikarpov, a medically trained doctor that has recently completed his PhD studies, has written two papers showing the prospect of using Miltuximab® in bladder cancer and glioblastoma respectively.
Finally, our collaboration with Professors Pam Russell and Colleen Nelson from the Australian Prostate Cancer Research Centre at the Queensland University of Technology, has resulted in a publication by Dr Mei-Chun Yeh, demonstrating how radiolabelled Miltuximab® can be used for imaging and immunotherapy thus making it a potential theranostic.
Dr Brad Walsh, CEO of GlyTherix commented “The opportunity to target Glypican-1 bearing tumours in cancers with high unmet need such as glioblastoma, esophagus, bladder and pancreas as well as some of the most prevalent cancers like prostate and breast using Miltuximab® makes this an exciting group of papers well worth reviewing. It also augurs well for our planned clinical program building on our First-in-Human trial.”
Links to the four papers are provided below. The company would be pleased to answer your questions regarding the technology, our clinical program and how you can become involved in this exciting story as an investor or supporter.